Optimal Combination Therapy After Nevirapine Exposure

Trial Profile

Optimal Combination Therapy After Nevirapine Exposure

Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Nevirapine (Primary) ; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir; Tenofovir dipivoxil fumarate; Tenofovir disoproxil fumarate
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms OCTANE; OCTANE-1
  • Most Recent Events

    • 26 Jul 2017 Results (n=253) of secondary analysis to understand the impact ART drugs on pregnancy and birth outcomes among women from this trial and HPTN 052 and ACTG A5175 trial, were presented at the 9th International AIDS Society Conference on HIV Science
    • 10 Jun 2017 Biomarkers information updated
    • 08 Mar 2012 Extension study results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top